Aside from MET exon 14 skip mutations, are there other targetable MET mutations or fusions that you would consider for TKI therapy?

MET exon 14 skipping mutations are a heterogeneous group of mutations that result in the absence of a juxtamembrane domain leading to constitutive activity of the MET receptor. Over 100 genetic variants have been described. In addition to MET exon 14 skipping mutations, MET amplification has also be...